Does USTEKINUMAB Cause Hypertransaminasaemia? 47 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 47 reports of Hypertransaminasaemia have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.1% of all adverse event reports for USTEKINUMAB.
47
Reports of Hypertransaminasaemia with USTEKINUMAB
0.1%
of all USTEKINUMAB reports
11
Deaths
18
Hospitalizations
How Dangerous Is Hypertransaminasaemia From USTEKINUMAB?
Of the 47 reports, 11 (23.4%) resulted in death, 18 (38.3%) required hospitalization, and 30 (63.8%) were considered life-threatening.
Is Hypertransaminasaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 47 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Hypertransaminasaemia?
METHOTREXATE (436)
ACETAMINOPHEN (326)
PACLITAXEL (318)
CARBOPLATIN (304)
PEMBROLIZUMAB (231)
ATORVASTATIN (207)
CYCLOPHOSPHAMIDE (202)
PREDNISONE (198)
GEMCITABINE (196)
DEXAMETHASONE (169)
Which USTEKINUMAB Alternatives Have Lower Hypertransaminasaemia Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE